65,437 trials
Atrophy of Edentulous Alveolar Ridge · Partial Edentulism
Primary: Resonance Frequency Values of Dental Implants — 83.04; 80.59 units on a scale
Chronic Low Back Pain
Primary: Cumulative Summed Pain Intensity Difference (SPID+) — 4.6; 6.3; 6.7; 5.2 units on a scale
Obesity
Primary: Percent Change From Baseline in Body Weight at Week 26 — -0.6; -4.1; -1.9; -7.5 Percent Change — p=<0.001
Parkinson's Disease
Primary: Percentage of Kinesia One Assessments Performed — 99 percentage of home assessments completed
Epilepsies, Partial
Primary: Number of Participants With Treatment-Related Adverse Events — 5 Participants
B-cell Small Lymphocytic Lymphoma Recurrent
Primary: Response — 3; 2; 1; 4 participants
Obesity · Schizophrenia · Schizoaffective Disorder
Primary: Change in Body Weight From Baseline — -3.40; 1.37 kg
Low Back Pain
Primary: Change From Baseline in Pain on 11- Point Numerical Rating Scale at Week 7 — 1.32; 3.63 units on a scale — p=<0.001
Prostate Cancer
Primary: PSA Response Rate — 38; 23 participants
Hoarding
Primary: The Saving Inventory-Revised (SI-R) Total Score — 66; 60; 46; 45 units on a scale
Seasonal Allergic Rhinitis
Primary: Change From Baseline Over 2 Weeks in Participant-Reported Morning and Evening Reflective Total Nasal Symptom Scores (TNSS) — 7.81; 7.71; -2.85; -2.68 scores on a scale…
Prostate Adenocarcinoma · Recurrent Prostate Carcinoma · Stage IV Prostate Cancer
Primary: Undetectable PSA Rate — 42; 34 participants — p=0.16
Friedreich's Ataxia
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 3; 0; 4; 5 participants
Polycystic Ovary Syndrome
Primary: Percentage of Participants With Ovulation Detected by Ultrasound — 52.5; 40.4 percentage of participants — p=0.3
Advanced Non Small Cell Lung Cancer · Advanced (Inoperable) Non Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) for Dose Expansion Population — 61.7 % of participants